0001209191-23-050840.txt : 20230929
0001209191-23-050840.hdr.sgml : 20230929
20230929141535
ACCESSION NUMBER: 0001209191-23-050840
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230927
FILED AS OF DATE: 20230929
DATE AS OF CHANGE: 20230929
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Crombez Eric
CENTRAL INDEX KEY: 0001653052
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36276
FILM NUMBER: 231294602
MAIL ADDRESS:
STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC.
STREET 2: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ultragenyx Pharmaceutical Inc.
CENTRAL INDEX KEY: 0001515673
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 272546083
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 415-483-8800
MAIL ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-09-27
0
0001515673
Ultragenyx Pharmaceutical Inc.
RARE
0001653052
Crombez Eric
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT
NOVATO
CA
94949
0
1
0
0
EVP and Chief Medical Officer
0
Common Stock
30512
D
Stock Option (Right to Buy)
67.37
2023-09-27
4
A
0
2351
0.00
A
2027-03-01
Common Stock
2351
2351
D
Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
On March 1, 2022, the Reporting Person was granted an option to purchase 2,351 shares of common stock. The option vests upon the achievement of specified performance criteria. Upon achievement of the performance criteria, 1/3 of the option vests on the date of certification by the Issuer's compensation committee of achievement of the performance criteria, 1/3 of the option vests on March 1, 2024 and 1/3 of the option vests on March 1, 2025. On September 27, 2023, the Issuer's compensation committee certified achievement of the performance criteria for the option, resulting in the vesting of the option of 784 shares on that date.
/s/ Karah Parschauer, attorney-in-fact
2023-09-29